

Formulary Update

March 2023

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since January 2023. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Alphosyl 2 in 1	Coal tar shampoo	13.9.1	Withdrawn from market
Desflurane	Inhaled anaesthetic	15.1.2	Scottish Government advise against use on environmental grounds

Additions	Indication	Adult Medicines Formulary entry/ rationale	
Famotidine	Added to Preferred List as preferred H2 antagonist option	1.3.1	Formulary appeal
Oritavancin	Added to Total Formulary for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults; restrictions to use apply, see Formulary entry for details.	5.1.4	Formulary appeal

Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
---	----------------------------------	---	--

Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Chronic kidney disease	New section 7.5 created to house medicines licensed for this condition	7.5	
Eplerenone	Restrictions of use changed to align with GGC heart failure treatment guideline (in development), see Formulary entry for details.	2.2.3	Formulary appeal
Metolazone	Prescribing note added highlighting that now available as licensed product Xaqua and this is the preferred preparation in GGC	2.2.1	
Oxycodone oral liquid formulations	Prescribing note changed highlight that Shortec brand is no longer available and oral liquids should be prescribed generically	4.7.2	